CY1115376T1 - Βελτιωμενη μεθοδος - Google Patents
Βελτιωμενη μεθοδοςInfo
- Publication number
- CY1115376T1 CY1115376T1 CY20141100562T CY141100562T CY1115376T1 CY 1115376 T1 CY1115376 T1 CY 1115376T1 CY 20141100562 T CY20141100562 T CY 20141100562T CY 141100562 T CY141100562 T CY 141100562T CY 1115376 T1 CY1115376 T1 CY 1115376T1
- Authority
- CY
- Cyprus
- Prior art keywords
- lenalidomide
- crystalline
- isoindol
- dione
- piperidine
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 abstract 4
- 229960004942 lenalidomide Drugs 0.000 abstract 3
- JKPJLYIGKKDZDT-UHFFFAOYSA-N 3-(7-nitro-3-oxo-1h-isoindol-2-yl)piperidine-2,6-dione Chemical compound C1C=2C([N+](=O)[O-])=CC=CC=2C(=O)N1C1CCC(=O)NC1=O JKPJLYIGKKDZDT-UHFFFAOYSA-N 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Optical Communication System (AREA)
- Lighting Device Outwards From Vehicle And Optical Signal (AREA)
- Glass Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN383KO2009 | 2009-03-02 | ||
| IN463KO2009 | 2009-03-16 | ||
| EP10707950.1A EP2403845B1 (en) | 2009-03-02 | 2010-03-01 | Improved process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1115376T1 true CY1115376T1 (el) | 2017-01-04 |
Family
ID=54290149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20141100562T CY1115376T1 (el) | 2009-03-02 | 2014-07-24 | Βελτιωμενη μεθοδος |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8946265B2 (enExample) |
| EP (1) | EP2403845B1 (enExample) |
| JP (1) | JP5727944B2 (enExample) |
| CN (1) | CN102414196A (enExample) |
| AU (1) | AU2010220204B2 (enExample) |
| CA (1) | CA2753241C (enExample) |
| CY (1) | CY1115376T1 (enExample) |
| DK (1) | DK2403845T3 (enExample) |
| ES (1) | ES2487215T3 (enExample) |
| HR (1) | HRP20140686T1 (enExample) |
| NZ (1) | NZ595492A (enExample) |
| PL (1) | PL2403845T3 (enExample) |
| PT (1) | PT2403845E (enExample) |
| SI (1) | SI2403845T1 (enExample) |
| SM (1) | SMT201400100B (enExample) |
| WO (1) | WO2010100476A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| TWI475014B (zh) * | 2009-09-17 | 2015-03-01 | Scinopharm Taiwan Ltd | 固體形態的３－（４－胺基－１－側氧基－１，３－二氫－異吲哚－２－基）－哌啶－２，６－二酮及其製造方法 |
| WO2011064574A1 (en) | 2009-11-24 | 2011-06-03 | Generics [Uk] Limited | Hplc method for detecting lenalidomide |
| EP2545043B1 (en) | 2010-03-08 | 2019-04-24 | Natco Pharma Limited | Anhydrous lenalidomide form-i |
| CA2802853C (en) | 2010-06-16 | 2016-07-26 | Bruce Chandler May | Use of levocetirizine and montelukast in the treatment of influenza, common cold and inflammation |
| WO2013005229A1 (en) * | 2011-07-05 | 2013-01-10 | Hetero Research Foundation | Process for lenalidomide |
| CA2842316A1 (en) | 2011-07-19 | 2013-01-24 | Amplio Pharma, Llc | Urea cocrystal of 3-(4-amin0-1-0x0-1,3 dihydro-isoindol-2-yl)piperidine-2,6-dione |
| CN102838586A (zh) * | 2012-09-20 | 2012-12-26 | 重庆泰濠制药有限公司 | 一种制备来那度胺的方法 |
| WO2014164299A1 (en) | 2013-03-13 | 2014-10-09 | Inflammatory Response Research, Inc. | Use of levocetirizine and montelukast in the treatment of autoimmune disorders |
| EP3308835B1 (en) | 2013-03-13 | 2020-01-01 | Inflammatory Response Research, Inc. | Use of levocetirizine and montelukast in the treatment of traumatic injury |
| CN105263579B (zh) | 2013-03-13 | 2020-01-10 | 炎症反应研究公司 | 左西替利嗪和孟鲁司特在治疗血管炎中的用途 |
| WO2014160686A1 (en) * | 2013-03-26 | 2014-10-02 | Celgene Corporation | Solid forms comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione and a coformer, compositions and methods of use thereof |
| CN103601717A (zh) * | 2013-10-09 | 2014-02-26 | 湖南华腾制药有限公司 | 一种来那度胺的新型制备方法 |
| LV14985B (lv) | 2013-10-14 | 2015-06-20 | Latvijas Organiskās Sintēzes Institūts | Lenalidomīda iegūšanas process |
| EP3137450A2 (en) * | 2014-04-26 | 2017-03-08 | Shilpa Medicare Limited | Crystalline lenalidomide process |
| WO2016024286A2 (en) * | 2014-08-11 | 2016-02-18 | Avra Laboratories Pvt. Ltd. | An improved process for synthesis of lenalidomide |
| MX369968B (es) * | 2014-08-19 | 2019-11-27 | Synthon Bv | Procedimiento para elaborar la forma cristalina a de lenalidomida. |
| JP2017526728A (ja) | 2014-09-15 | 2017-09-14 | インフラマトリー・レスポンス・リサーチ・インコーポレイテッド | 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト |
| WO2017109041A1 (en) * | 2015-12-22 | 2017-06-29 | Synthon B.V. | Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant |
| US10899793B2 (en) | 2016-05-27 | 2021-01-26 | Regents Of The University Of Minnesota | Melanocortin ligands and methods of use thereof |
| US11124541B2 (en) | 2016-10-18 | 2021-09-21 | Regents Of The University Of Minnesota | Chimeric melanocortin ligands and methods of use thereof |
| JP2020535192A (ja) * | 2017-09-27 | 2020-12-03 | バイオコン・リミテッド | レナリドミドの結晶形 |
| WO2019138424A1 (en) * | 2018-01-11 | 2019-07-18 | Natco Pharma Limited | Stable pharmaceutical compositions comprising lenalidomide |
| US11332499B2 (en) | 2018-08-16 | 2022-05-17 | Regents Of The University Of Minnesota | Cyclic peptides and methods of use thereof |
| CN111196800B (zh) * | 2018-11-19 | 2022-10-11 | 欣凯医药化工中间体（上海）有限公司 | 一种制备来那度胺的方法 |
| WO2022144924A1 (en) * | 2021-01-04 | 2022-07-07 | Avra Laboratories Pvt. Ltd. | An improved process for synthesis of lenalidomide |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| ES2438725T3 (es) | 2004-09-03 | 2014-01-20 | Celgene Corporation | Procedimientos para la preparación de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas |
| US8304250B2 (en) | 2007-04-16 | 2012-11-06 | Momenta Pharmaceuticals, Inc. | Multi-dimensional chromatographic methods for separating N-glycans |
| WO2009077784A2 (en) | 2007-12-14 | 2009-06-25 | Generics [Uk] Limited | Hpcl method for analysing clopidogrel |
| CA2717326C (en) | 2008-03-11 | 2018-10-23 | Dr. Reddy's Laboratories Ltd. | Preparation of lenalidomide |
| CN102272118A (zh) | 2008-11-03 | 2011-12-07 | 基因里克斯(英国)有限公司 | 来那度胺的晶型及其制备方法 |
| WO2011064574A1 (en) | 2009-11-24 | 2011-06-03 | Generics [Uk] Limited | Hplc method for detecting lenalidomide |
-
2010
- 2010-03-01 SI SI201030679T patent/SI2403845T1/sl unknown
- 2010-03-01 WO PCT/GB2010/050352 patent/WO2010100476A2/en not_active Ceased
- 2010-03-01 JP JP2011552515A patent/JP5727944B2/ja active Active
- 2010-03-01 CA CA2753241A patent/CA2753241C/en active Active
- 2010-03-01 NZ NZ595492A patent/NZ595492A/xx not_active IP Right Cessation
- 2010-03-01 ES ES10707950.1T patent/ES2487215T3/es active Active
- 2010-03-01 DK DK10707950.1T patent/DK2403845T3/da active
- 2010-03-01 HR HRP20140686AT patent/HRP20140686T1/hr unknown
- 2010-03-01 US US13/254,249 patent/US8946265B2/en active Active
- 2010-03-01 AU AU2010220204A patent/AU2010220204B2/en not_active Ceased
- 2010-03-01 PL PL10707950T patent/PL2403845T3/pl unknown
- 2010-03-01 PT PT107079501T patent/PT2403845E/pt unknown
- 2010-03-01 CN CN2010800195527A patent/CN102414196A/zh active Pending
- 2010-03-01 EP EP10707950.1A patent/EP2403845B1/en active Active
-
2014
- 2014-07-24 CY CY20141100562T patent/CY1115376T1/el unknown
- 2014-07-28 SM SM201400100T patent/SMT201400100B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI2403845T1 (sl) | 2014-09-30 |
| EP2403845B1 (en) | 2014-04-30 |
| US20120071509A1 (en) | 2012-03-22 |
| CA2753241C (en) | 2015-06-16 |
| NZ595492A (en) | 2013-07-26 |
| US8946265B2 (en) | 2015-02-03 |
| DK2403845T3 (da) | 2014-08-04 |
| SMT201400100B (it) | 2014-11-10 |
| WO2010100476A3 (en) | 2011-06-16 |
| WO2010100476A2 (en) | 2010-09-10 |
| AU2010220204B2 (en) | 2015-10-08 |
| JP5727944B2 (ja) | 2015-06-03 |
| AU2010220204A1 (en) | 2011-10-20 |
| HRP20140686T1 (hr) | 2014-09-26 |
| CN102414196A (zh) | 2012-04-11 |
| CA2753241A1 (en) | 2010-09-10 |
| EP2403845A2 (en) | 2012-01-11 |
| PL2403845T3 (pl) | 2014-09-30 |
| PT2403845E (pt) | 2014-08-04 |
| JP2012519207A (ja) | 2012-08-23 |
| ES2487215T3 (es) | 2014-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1115376T1 (el) | Βελτιωμενη μεθοδος | |
| EA201391318A1 (ru) | Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2,6-диона и их фармацевтические композиции и применение | |
| CY1119474T1 (el) | Κρυσταλλικες μορφες 5-χλωρο-ν2-(2-ισοπροποξυ-5-μεθυλ-4-πιπεριδιν-4-υλ-φαινυλ)-ν4[2-(προπανο-2-σουλφονυλ)-φαινυλ]-πυριμιδιν-2,4-διαμινης | |
| CY1122330T1 (el) | Συνθεσεις δισκιων μηλεϊνικης νερατινιμπης | |
| CY1117331T1 (el) | Αντισωματα προσδεσης στην εξωκυτταρικη περιοχη 4 του ανθρωπινου csf1r και η χρηση αυτων | |
| EA201001126A1 (ru) | Пирролопиримидины и пирролопиридины | |
| EA201171151A1 (ru) | Кристаллические трипептидные ингибиторы эпоксикетон-протеазы | |
| CY1118416T1 (el) | Υποκατεστημενες 4-φαινυλο-πυριδινες για τη θεραπεια ασθενειων που σχετιζονται με τον νκ-1 υποδοχεα | |
| MX345541B (es) | Formas solidas de (r)-1(2,2-difluorobenzo[d] [1,3]dioxol-5-il)-n-( 1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il) -1h-indol-5-il) ciclopropanocarboxamida. | |
| CY1110190T1 (el) | Παραγωγα πιπεραζινυλιου χρησιμα στην αγωγη των νοσων στις οποιες μεσολαβει ο υποδοχεας gpr38 | |
| EA201170884A1 (ru) | Производные пиперидина, пригодные в качестве антагонистов орексина | |
| GEP20135863B (en) | Substituted piperidines as ccr3 antagonists | |
| EA201390934A1 (ru) | Композиции и способы модулирования fxr | |
| CY1118630T1 (el) | Στερεες μορφες 3-(6-(1-(2,2-διφθοροβενζο[d][1,3]διοξολ-5-υλο)-κυκλοπροπανοκαρβοξαμ1δο)-3-μεθυλοπυριδιν-3-υλο)-βενζοϊκου οξεος | |
| EA201200741A1 (ru) | Способ получения этексилата дабигатрана | |
| EA201071291A3 (ru) | Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств | |
| CY1123426T1 (el) | Μεθοδος για τη ληψη κρυσταλλων αλατος μεγλουμινης του 1-(5,6-διχλωρο-1η-βενζο[d]ιμιδαζολ-2-υλο)-1η-πυραζολο-4-καρβοξυλικου οξεος | |
| CY1111927T1 (el) | Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων | |
| EA201070148A1 (ru) | Соединения и способы модулирования фарнезоидного рецептора x (fxr) | |
| MX385217B (es) | Antagonistas de actriib y dosificación y usos de los mismos. | |
| EA201590330A1 (ru) | Соли и твердые формы (s)-3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и включающие их композиции и способы их применения | |
| EA201101009A1 (ru) | АНТАГОНИСТЫ C5aR | |
| EA201290726A1 (ru) | Новые соли для получения фармацевтических композиций | |
| EA201391797A1 (ru) | 3-спироциклические пиперидиновые производные в качестве агонистов грелиновых рецепторов | |
| EA201100517A1 (ru) | Способ получения дабигатрана и его промежуточные соединения |